case_images: PMC6188590_01
case_images: CPK levels during statin therapy, before presenting to Rheumatology Clinic.
case_images: CRIRH2018-1215653.001.jpg
case_images: PMC6188590_01_CRIRH2018-1215653.001.jpg
case_images: fig1
case_images: While she was on therapy with atorvastatin, baseline CPK levels were in the 230 mg/dl, with the highest value being 529 mg/dl at the time of therapy discontinuation (Figure 1).
case_images: CPK levels after statin re-challenge and initiation of immunosuppressive therapy.
case_images: CRIRH2018-1215653.002.jpg
case_images: PMC6188590_01_CRIRH2018-1215653.002.jpg
case_images: fig2
case_images: CPK levels increased again to 586 mg/dl, and the sedimentation rate (ESR) was 51 mm/hr (Figure 2).
case_images: Muscle intrafascicular and perivascular lymphocytic inflammation (H&E, photomicrograph x100).
case_images: CRIRH2018-1215653.003.jpg
case_images: PMC6188590_01_CRIRH2018-1215653.003.jpg
case_images: fig3
case_images: The pathology report was consistent with inflammatory necrotizing myopathy (intrafascicular inflammation with muscle atrophy, the inflammation is predominantly intrafascicular with actively necrotic muscle fibers) (Figures 3 and 4).
case_images: Lymphocytic inflammation surrounding muscle fibers (H&E, photomicrograph x400).
case_images: CRIRH2018-1215653.004.jpg
case_images: PMC6188590_01_CRIRH2018-1215653.004.jpg
case_images: fig4
case_images: The pathology report was consistent with inflammatory necrotizing myopathy (intrafascicular inflammation with muscle atrophy, the inflammation is predominantly intrafascicular with actively necrotic muscle fibers) (Figures 3 and 4).